Physician profile
Brad Penenberg
NPI 1831122266
$3,997,734.86
in general payments reported to CMS, 2019-2025
22 companies · $103K in 2025
The $103K reported for 2025 was more than what 97% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $543K · 2020: $562K · 2021: $1.1M · 2022: $948K · 2023: $594K · 2024: $190K · 2025: $103K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $848K · Consulting Fee: $28K · Travel and Lodging: $7,426 · Food and Beverage: $3,223 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $848,372.86 |
| Consulting Fee | $28,433.00 |
| Travel and Lodging | $7,426.04 |
| Food and Beverage | $3,222.52 |
| Education | $187.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $2,421,993.51 | 2019-2025 | Persona, Persona Partial Knee System, Ncb |
| Microport Orthopedics INC | $1,244,943.78 | 2019-2025 | Mpo Hip System |
| Medacta USA, INC. | $255,041.75 | 2019-2021 | |
| Uoc USA INC | $68,562.14 | 2019-2025 | Resolve, U2, Conformity, U-Motion II and Ustar II, Mhr |
| Smith+Nephew, INC. | $4,913.70 | 2019-2023 | Real Intelligence |
| Shalby Advanced Technologies, INC. | $527.19 | 2024 | Cks - Vitalite, Consensus Knee System |
| Stryker Corporation | $511.86 | 2022-2025 | Mako, Triathlon |
| Siemens Medical Solutions USA, INC. | $367.35 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $196.14 | 2019-2022 | |
| Lima USA, INC. | $140.98 | 2019 | |
| Zyla Life Sciences, INC. | $101.28 | 2019-2020 | |
| Fidia Pharma USA INC. | $94.62 | 2019-2020 | |
| Intellijoint Surgical INC. | $79.12 | 2020 | |
| Biocomposites INC | $75.25 | 2023-2024 | Stimulan |
| Think Surgical, INC. | $54.32 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $36.04 | 2019-2021 | |
| Merz Pharmaceuticals, LLC | $28.98 | 2023 | Xeomin |
| Pfizer INC. | $21.59 | 2020 | |
| Daiichi Sankyo INC. | $17.26 | 2019 | |
| Assertio Therapeutics, INC. | $14.50 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $13.50 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$6,375,199.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Penenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.